As Trump Prepares Plan to Lower Drug Prices, Big Pharma Girds for a Fight

A longtime aide to former Representative John D. Dingell, Democrat of Michigan, works for the Pharmaceutical Research and Manufacturers of America. An aide to former Senator Tom Harkin, Democrat of Iowa, who was the chairman of the Senate well being committee, is now a high lobbyist for Merck.

The door swings in each instructions. For six years, Gary Andres was the Republican employees director of the House Energy and Commerce Committee, which is accountable for laws that impacts prescribed drugs and the F.D.A. In February 2017, he grew to become a senior govt vp of the Biotechnology Innovation Organization, a commerce group that lobbies for biotech firms.

Then he returned final month to Capitol Hill to develop into the Republican employees director of the Ways and Means Committee, which has jurisdiction over Medicare, together with its funds for prescribed drugs.

Ryan Long, former chief well being counsel on the Energy and Commerce Committee, joined BGR Government Affairs in February 2013. In lobbying disclosure reviews filed by BGR, he was listed as a lobbyist for Amgen, Celgene, Gilead, Lilly and Merck, amongst different shoppers. He returned to the committee this March because the deputy employees director.

Retired lawmakers additionally present up as lobbyists.

Among those that are listed as having lobbied for the Pharmaceutical Research and Manufacturers of America in recent times are former Senator Jon Kyl of Arizona and former Representative Bill Paxon of New York, each Republicans. Former Representative Ed Whitfield, Republican of Kentucky, is listed as lobbying for AstraZeneca, Genentech and Johnson & Johnson, amongst different firms.

Whether that firepower will nonetheless be efficient is an open query.

“Nearly every major decision in this administration so far has favored the pharmaceutical industry,” mentioned Ronny Gal, a securities analyst at Sanford C. Bernstein & Company. “But investors are apprehensive about the long-term horizon. Every other country has acted to control drug costs, and the view is that eventually the United States will have to do so.”

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *